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A rat carcinogenicity bioassay (CaBio) of quinacrine was reanalyzed to investigate its mode of tumor
induction. Quinacrine’s effects in the rat uterus when administered as a slurry in methylcellulose were
contrasted with the human clinical experience which uses a solid form of the drug, to determine the rele-
vance of the tumors produced in the rat to safe clinical use of quinacrine for permanent contraception
(QS). A review was performed of the study report, dose feasibility studies, and clinical evaluations of
women who had undergone the QS procedure. The top three doses of quinacrine in the CaBio exceeded
the maximum tolerated dose, and produced chronic damage, including inﬂammation, resulting in repro-
ductive tract tumors. Chronic inﬂammation was signiﬁcantly correlated with the tumors; there was no
evidence of treatment-related tumors in animals without chronic inﬂammation or other reproductive
system toxicity. Because such permanent uterine damage and chronic toxicity have not been observed
in humans under therapeutic conditions, we conclude that this mode of action for tumor production will
not occur at clinically relevant doses in women who choose quinacrine for permanent contraception.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Since its development in the 1920s, quinacrine has been
successfully used for a wide variety of indications (Ehsanian
et al., 2011; Wallace, 1989), including as an oral treatment and
prophylactic for malaria in millions of American soldiers in the
South Paciﬁc during World War II. These soldiers were adminis-
tered quinacrine on a daily basis, sometimes for years. Quinacrine
has also been used to treat parasitic infections such as amoeba,
giardia and tapeworm. The discovery of the anti-inﬂammatory
properties of quinacrine led to its use in the treatment of refractory
lupus erythematosus, rheumatoid arthritis, bronchial asthma, and
other inﬂammatory and autoimmune disorders. Quinacrine is
commonly administered to patients for months at a time to controlsymptoms of these diseases. Although other drugs have been
developed that have superseded quinacrine for some indications,
it has remained USFDA-approved for malaria, giardia and tape-
worm, and has never been removed from use for safety concerns
(Ehsanian et al., 2011).
Quinacrine’s potential use as a nonsurgical method of perma-
nent contraception for women has been investigated for more than
35 years. Brieﬂy, seven pellets containing a total of 252 mg quina-
crine are placed transcervically into a woman’s uterus in two
administrations, one month apart, during the proliferative phase
of her menstrual cycle. The quinacrine interacts with fallopian tube
tissue to produce a 2–3 mm occlusive scar in the intramural por-
tion of the tube that permanently closes the tubal lumen, thereby
preventing the passage of sperm or egg. The quinacrine is either
expelled through the vagina (30%) or is absorbed by the vascular
system (Laufe et al., 1996). Since 1977, over 150,000 women have
used the quinacrine system of permanent contraception (QS), with
no deaths or adverse events requiring hospitalization reported
(Lippes et al., 2003).
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S9 in the Salmonella mutagenicity (Ames) assay (Clarke et al.,
2001; Zeiger et al., 1988) and in the mouse lymphoma (L1578Y)
assay only without S9 (Clarke et al., 2001), and produces chromo-
some damage in mammalian cells in vitro (Clarke et al., 2001;
Krishnaja and Chauhan, 2000; Schuler et al., 2010). In contrast, qui-
nacrine is not clastogenic in the in vivo mouse bone marrow
micronucleus assay (Clarke et al., 2001) or in peripheral blood lym-
phocytes of female cynomolgus monkeys administered quinacrine
via intrauterine or i.v. routes (Blake et al., 1983).
Because of its in vitro mutagenicity, quinacrine was tested for
carcinogenicity in the mouse and rat. It was not carcinogenic in
the neonatal mouse assay when administered intraperitoneal
(i.p.) to male and female mice (Cancel et al., 2006), but did induce
tumors in the female rat when administered directly into the rat
uterus at doses exceeding the maximum tolerated dose (MTD),
i.e., doses that produced high mortality and/or irreparable (chron-
ic) target organ damage including ulceration, abdominal adhesions,
reproductive tract chronic inﬂammation, necrosis, atrophy, and
cystic degeneration (Cancel et al., 2010).
Although epidemiological studies of women receiving QS have
reported no increased risk of reproductive tract cancer, because
of quinacrine’s mutagenicity, the FDA and WHO recommended
that the molecular mechanisms of tumor induction in the rat can-
cer bioassay (CaBio) study be investigated. They also recommend-
ed that an additional epidemiology study be performed among
women who had received QS contraception.
This article presents an extended reanalysis of the original data
from the rat CaBio laboratory report in the context of the acute and
chronic toxicity of quinacrine to test the potential mode of action of
tumor development suggested by McConnell et al. (2010). The goal
of this reanalysis was: (a) to determine the probable underlying
cause for the tumors in the rat CaBio; (b) to propose a likely mode
of action for the tumor induction; and (c) to assess the relevance of
the rat studywith respect to the human clinical experiencewith QS,
and its potential risk to humans under conditions of use.
The ﬁndings from short-term rat studies and the prechronic
studies (McConnell et al., 2010) are also included in the total
weight of evidence evaluation of the induction and signiﬁcance
of the reproductive tract tumors seen in the rat CaBio, in addition
to the human clinical experience and cancer epidemiology studies
of women receiving QS.1.1. Cancer studies of quinacrine
1.1.1. Neonatal mouse studies
Quinacrine 2HCl dihydrate was not carcinogenic in male or
female Crl:CD-1 mice using two i.p. doses of 10, 50, and 150 mg/
kg, suspended in 1% (w/v) carboxymethylcellulose in saline, onTable 1
Experimental design of rat the 2-year quinacrine cancer bioassay.
Group no. Test material Dose (mg/kg)a Num
Dose
Day 0 Day 21
1 1% MCb 0 0 60
2 1% MCb 0 0 60
3 Quinacrine 2HClc 10 10 60
4 Quinacrine 2HClc 70 70 60
6 Quinacrine 2HClc 70 250 35
5 Quinacrine 2HClc 70 350 33
a Doses represent active ingredient (quinacrine dihydrochloride dihydrate). Each anim
injected into the end of each uterine horn in an attempt to minimize leakage of the qui
b 1% (w/v) methylcellulose in 0.9% saline.
c Slurry in 1% (w/v) methylcellulose in 0.9% saline.postpartum days 8 and 15, and examined for tumors 52 weeks fol-
lowing dosing (Cancel et al., 2006). The 150 mg dose was lethal to
9/28 males (32%) and 5/28 (18%) females following the second (day
15) administration – the deaths occurring either during, or shortly
after, dosing. Because of the anticipated toxicity, additional
animals were added after the initial dosing. As a consequence,
the second dose was lowered to 100 mg/kg. Of the additional eight
males added and dosed with 100 mg/kg on day 15, three died
during dosing. The animals were necropsied 52 weeks following
quinacrine administration; no increases in tumors over control
group levels were seen in either sex (Cancel et al., 2006).
1.1.2. Rat 2-year CaBio
A 2-year cancer bioassay of quinacrine 2HCl dihydrate using the
route of exposure (transcervical instillation) intended for women
undergoing QS was conducted in rats. This CaBio reported high,
treatment-related mortality at the top doses, and an increased inci-
dence of unusual and rare types of neoplasms in the uterus, vagina
and/or cervix at the top three doses (Cancel et al., 2010). A pre-
liminary assessment of the neoplasms reported in this study was
presented in a companion paper by McConnell et al. (2010).
The design of this 2-year rat study is addressed in detail here
because a description of the protocol design, and its consequences,
is critical to an understanding of the mechanisms and relevance of
tumor induction.
Young, sexually mature (approximately 57–68 days old), albino
female Crl:CD(SD)IGS BR rats received two doses of quinacrine
2HCl as slurry in 1% methylcellulose (MC) into each uterine horn
via the vagina and cervix using a 22 gauge spinal needle with a
blunted end ﬁtted on a syringe approximately 21 days apart during
diestrus (because the day of administration depended on the ani-
mal being in diestrus, animals could not be dosed on the same
day). The uteri were ‘sealed’ after each dosing with a plug of 3%
MC to prevent leakage of the slurry. Despite information from prior
range-ﬁnding studies that the higher doses would be toxic to the
animals and would produce inﬂammation among the survivors
(Cancel et al., 2010), the high doses were used in an attempt to
mimic, in the rat uterus, the ﬁbrosis of the fallopian tube that is
found in humans.
The rats were observed for 23 months after administration of
the second dose. The study design included two identical MC con-
trol groups, but there was no untreated, or sham-treated, control
group (Table 1). The original study design called for three quina-
crine treatment groups, with Day 0/Day 21 doses of 10/10, 70/70,
and 70/350 mg/kg, respectively, with half of each dose delivered
to each of the rats’ two uterine horns.
The CaBio was divided into two ‘‘phases’’: (1) a ‘‘dosing phase,’’
extending one month after the administration of the second dose,
and, (2) an ‘‘observation phase,’’ where the surviving animals were
observed for the remainder of the experiment. Since high mortalityber of animals
d Entering ‘‘observation phase’’ Survived to terminal sacriﬁce
50 13
50 14
50 13
50 17
24 5
21 10
al was dosed with ½ dose per uterine horn. A plug of 3 ll of 3% methylcellulose was
nacrine.
Table 2
Incidence of reproductive system neoplasms in the quinacrine rat CaBio.a
Quinacrine (mg/kg)b 0/0 0/0 10/10 70/70 70/250 70/350
Group number 1 2 3 4 6 5
Total number of rats 50 50 50 50 24 21
Cervix: number examined 49 49 50 49 23 21
Benign squamous cell papilloma 0 0 0 1 (2) 1 (4) 0
Benign ﬁbroma 0 1 (2) 1 (2) 0 0 0
Malignant squamous cell carcinoma 0 0 0 0 1 (4) 2 (10)
Malignant basal-squamous cell carcinoma 0 0 0 0 1 (4) 0
Malignant schwannoma 0 0 1 (2) 1 (2) 0 0
Uterus: number examined 50 50 50 50 24 21
Benign endometrial stromal polyp 5 (10) 9 (18) 4 (8) 1 (2) 2 (8) 1 (5)
Benign hemangioma 0 0 0 1 (2) 0 1 (5)
Benign granular cell tumor 0 0 0 1 (2) 0 0
Benign mixed mullerian tumor 0 0 0 1 (2) 0 0
Malignant endometrial carcinoma 0 0 0 1 (2) 0 2 (10)
Malignant carcino-sarcoma 0 0 0 0 1 (4) 0
Malignant stromal sarcoma 0 0 0 1 (2) 1 (4) 0
Malignant squamous cell carcinoma 0 0 0 1 (2) 0 0
Malignant yolk sac carcinoma 0 0 0 1 (2) 0 0
Malignant leiomyosarcoma 0 0 1 (2) 0 0 1 (5)
Malignant schwannoma 1 (2) 0 0 0 0 2 (10)
Malignant hemangiosarcoma 0 0 0 0 0 1 (5)
Vagina: number examined 50 49 48 49 24 18
Malignant squamous cell carcinoma 0 0 0 1 (2) 4 (17)* 0
Reproductive tract: number of uncommon neoplasmsc 1 1 3 10 9 9
Reproductive tract: number of animals with uncommon neoplasms 1 (2) 1 (2) 3 (6) 9 (18)* 7 (29)* 6 (29)*
a Values in the table represent incidence of the ﬁnding and % incidence (in parentheses).
b Split doses administered on Days 0 and 21 of study.
c Excludes endometrial stromal polyps, which are common tumors in rats.
* p < 0.01 versus pooled controls by Fisher’s exact test.
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ten extra animals were added to each group, with the plan of cul-
ling the groups to 50 animals each at the beginning of the ‘‘obser-
vation phase.’’
During the ‘‘dosing phase,’’ 12 of the 33 rats (36%) in the high-
dose group (Group 5) died or were euthanized in a moribund con-
dition shortly after administration of the second 350 mg dose. Due
to this higher than anticipated mortality, the remaining 27 rats in
Group 5 that had received the ﬁrst dose of 70 mg/kg but had not
received the second dose were combined with eight reserve rats
that had also been given a ﬁrst dose of 70 mg/kg, to form a new
group (Group 6; see Table 1) that received a second quinacrine
dose of 250 mg/kg. Of the 35 rats in this new group, 11 (31%) died
during the dosing phase.
This mortality in Groups 5 and 6 was associated with ulceration
through the uterine wall that resulted in quinacrine entering the
abdominal cavity. Death soon followed after administration or
within 30 days, following the development of quinacrine-induced
enteromegaly of the intestinal tract. During the ‘‘observation
phase’’ there were no signiﬁcant differences in mortality among
groups. Microscopic pathology was performed only on those ani-
mals entering the ‘‘observation phase.’’2. Statistical approach
For this re-assessment of the rat CaBio data, Groups 1 and 2 (-
control animals) were pooled, since there were no signiﬁcant dif-
ferences between the groups in any of the parameters analyzed
(see e.g., Tables 3–5 from Cancel et al., 2010). For this analysis,
Groups 5 and 6 were also pooled for the following reasons:
(1) Both dose groups produced the same percentage of animals
with uncommon reproductive system neoplasms: Group 6 –
7/24 (29%); Group 5 – 6/21 (29%)).(2) Mortality of animals immediately following Day 21 dosing
was similar in both groups: Group 5 – 12/33 (36%); Group
6 – 11/35 (31%).
(3) Low initial animal numbers due to toxicity: Group 6 – 35,
Group 5 – 33; and low subsequent 2-year survival numbers
in both groups (Group 6 – 5/24, Group 5 – 10/21), both of
which decrease the statistical power for detecting adverse
effects if the two groups are evaluated separately.
There were no statistically signiﬁcant differences in the inci-
dences of reproductive system tumors or in the incidence of any
of the reproductive tract non-neoplastic lesions among Groups 4,
5 and 6. Hence, these three groups were combined for the purpose
of assessing the possible association between these tumors and
reproductive system non-neoplastic lesions. In addition to the
individual organs, statistical analyses were conducted on all
reproductive tract (i.e., uterus, cervix, and vagina) neoplastic and
non-neoplastic lesions (Rhomberg et al., 2007).
Pairwise comparisons of the incidences of neoplastic and non-
neoplastic lesions between groups were made by Fisher’s exact
tests (Fisher, 1954) and also by the G-test (Sokal and Rohlf,
1981). These tests were also used to assess the correlation between
neoplastic and non-neoplastic lesions, and produced virtually iden-
tical results. The results given in the text are from Fisher’s exact
test, which was carried out using http://www.langsrud.com/ﬁsh-
er.htm.3. Results
3.1. Findings of the extended analysis of the rat CaBio
3.1.1. Gross necropsy results
At gross necropsy, there was clear evidence of damage to the
uterus, as reﬂected by signiﬁcantly increased incidences of large
Table 3
Summary of non-neoplastic reproductive tract lesion incidence in the quinacrine CaBio.
Quinacrine (mg/kg) 0/0 10/10 70/70 70/250 and 70/350
Group number 1 and 2 3 4 5 and 6
I/N (%)a I/N (%) I/N (%) I/N (%)
Vagina
Subacute (chronic active)/chronic inﬂammation 2/99 (2) 3/48 (6) 7/49 (14)** 8/42 (19)**
Erosion(s)/ulcer(s) 0/99 (0) 0/48 (0) 0/49 (0) 3/42 (7)*
Fibrosis 0/99 (0) 0/48 (0) 1/49 (2) 0/42 (0)
Cervix
Subacute (chronic active)/chronic inﬂammation 7/98 (7) 2/50 (4) 9/49 (18)* 14/44 (32)**
Fibrosis 0/98 (0) 1/50 (2) 1/49 (2) 0/44 (0)
Uterus (uterine horns)
Necrosis (with/without dystrophic mineral deposits) 0/100 (0) 2/50 (4) 6/50 (12)** 5/45 (11)**
Acute/subacute inﬂammation 2/100 (2) 1/50 (2) 5/50 (10)* 5/45 (11)*
Atrophy 12/100 (12) 13/50 (26)* 30/50 (60)** 34/45 (76)**
Erosion(s)/ulcer(s) 2/100 (2) 1/50 (2) 4/50 (8) 4/45 (9)
Cystic degeneration 0/100 (0) 0/50 (0) 18/50 (36)** 16/45 (36)**
Subacute (chronic active)/chronic inﬂammation 14/100 (14) 5/50 (10) 21/50 (42)** 20/45 (44)**
Endometrium – stromal ﬁbrosis 31/100 (31) 18/50 (36) 14/50 (28) 6/45 (13)
Serosa – ﬁbrosis 1/100 (1) 0/50 (0) 2/50 (4) 0/45 (0)
Other
Adhesions (abdominal cavity) 0/100 (0) 2/50 (4) 5/50 (10)** 11/45 (24)**
Hypercellular marrow any bone 32/100 (32) 16/50 (32) 24/50 (48)* 26/45 (58)**
Subacute (chronic active)/chronic inﬂammation of the reproductive tract 20/100 (20) 9/50 (18) 31/50 (62)** 25/45 (56)**
Inﬂammatory/mixed inﬂammatory cells of the reproductive tract 100/100 (100) 50/50 (100) 50/50 (100) 44/45 (98)
a I/N, incidence/number of animals examined.
* p < 0.05 by Fisher’s exact test (comparison to controls).
** p < 0.01 by Fisher’s exact test (comparison to controls).
Table 4
Correlation between reproductive tract chronic inﬂammation and uncommon
reproductive system tumors in Groups 4–6.
Tumor incidence
Animals with no chronic inﬂammation 8% (3/39)
Animals with chronic inﬂammation 34% (19/56)*
Animals with chronic inﬂammation at >1 site
(vagina, cervix and uterus)
67% (12/18)**
* p = 0.002 (compared to animals with no chronic inﬂammation); Fisher’s exact
test.
** p < 0.001 (compared to animals with no chronic inﬂammation); Fisher’s exact
test.
Table 5
Incidence of reproductive tract chronic inﬂammation in the quinacrine study.
Group number
(dose)
1 and 2
(control)
3 (10/10
mg/kg)
4–6 (70/70; 70/350;
70/250 mg/kg)
No tumor Tumor
Chronic inﬂammation 20%
(20/100)
18%
(9/50)
51%
(37/73)
86%
(19/22)
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Groups 4–6 relative to controls (data not shown).3.1.2. Reproductive tract neoplasms
The only neoplasms that showed a relationship to quinacrine
administration were in the reproductive tract. The overall
incidence of uncommon (those not normally found in the rat
reproductive tract) neoplasms was signiﬁcantly increased
(p < 0.01) in Groups 4–6 relative to controls (Table 2).3.1.3. Non-neoplastic lesions of the reproductive tract
The incidences of selected non-neoplastic lesions are shown in
Table 3. Many lesions in the rats dosed with 70/70 mg/kg and high-
er were clearly associated with exposure to quinacrine and MC.These included subacute (chronic active)/chronic inﬂammation,
necrosis, atrophy, and cystic degeneration.
The results presented in this table clearly show that chronic
inﬂammatory lesions of the reproductive tract were induced in
Groups 4–6, and that Group 3 did not show any increase in inﬂam-
matory lesions when compared to the MC control Groups 1 and 2.
Relevant to the rationale for selection of the doses, i.e., produc-
tion of ﬁbrosis in the rat uterus to mimic the fallopian tube ﬁbrosis
produced clinically in women, there was no increase in such ﬁbro-
sis in the treated animals. The incidence of ﬁbrosis in the reproduc-
tive tract either decreased with respect to dose or remained
statistically equivalent to controls (see Table 3). No lumen closure
or uterine occlusions were noted in the individual animal data.
3.1.4. Lesions in other tissues related to quinacrine exposure
Adhesions between organs in the abdominal cavity were
increased in incidence relative to controls (p < 0.01) in Groups 4–
6 (Table 3). Based on the acute study performed following
completion of the CaBio (McConnell et al., 2010; unpublished
results), these adhesions appeared to be the result of perforations
of the uterine horn and leakage of quinacrine and MC into the
abdominal cavity due to the ulcerative effects of the chemical at
the high dose levels administered. Hypercellular bone marrow
(sternal, femoral and tibial combined) also showed a signiﬁcantly
increased incidence relative to controls in Groups 4 (p < 0.05), 5
and 6 (p < 0.01), and was attributed to the secondary effects of
the chronic inﬂammation in the reproductive tract.
3.1.5. Correlation of non-neoplastic lesions and tumor development
One lesion showing a highly signiﬁcant (p = 0.002) correlation
with the reproductive system tumors in Groups 4–6 was chronic
inﬂammation (Table 4). The correlation was even stronger
(p < 0.001) for those animals having chronic inﬂammation at more
than one reproductive tract site (vagina, cervix, and uterus; Table 4).
Only three animals in Groups 4–6 had reproductive system
tumors in the absence of chronic inﬂammation. One of these
animals had necrosis, another toxic lesion that showed a highly
J.K. Haseman et al. / Regulatory Toxicology and Pharmacology 71 (2015) 371–378 375signiﬁcant (p < 0.001) association with tumor development, i.e.,
73% (8/11) of the animals in Groups 4–6 with necrosis had
reproductive system tumors compared with 17% (14/84) tumor
incidence for animals in those groups without necrosis. It is likely
that the two remaining animals with reproductive system tumors
in Groups 4–6 reﬂect the background incidence, since two animals
with reproductive system tumors were also seen in the controls
(see Table 2).
Alternatively, one animal had a malignant schwannoma. Since a
malignant schwannomawas seen in the control group this could be
considered a background tumor. The second animal had necrosis,
uterine tumors metastasized to several organs and a 7.9 cm mass
that could have obscured the chronic inﬂammation present. The
presence of chronic inﬂammation in the third animal could have
been overlooked since it is the only animal in the study (1/245)
where the presence of inﬂammatory cells is not recorded. Regard-
less, the evidence is very strong that the induction of chronic inﬂam-
mation and other chronic toxicities in the reproductive tract is
responsible for the formation of the reproductive tract tumors.
Another way to demonstrate the association between chronic
inﬂammation and reproductive system tumors is given in Table 5.
Chronic inﬂammation was not increased in Group 3 relative to con-
trols, but was increased in the Groups 4–6 tumor-free animals, and
further increased in the tumor-bearing animals. This supports the
conclusion that the chronic inﬂammation preceded tumor
development, created a uterine environment that fostered tumor
development, and was clearly not due to tumor formation. Chronic
inﬂammation was also reported in a short-term (42 day duration)
feasibility study described by Cancel et al. (2010).
3.2. Cancer studies of QS in humans
Studies of relatively small cohorts of women in Vietnam
(N > 2,800) and Chile (N = 1,492) treated with QS in clinical trials
showed no increased risk of reproductive tract cancer or other seri-
ous adverse events compared to IUD controls (Feldblumet al., 2012;
Sokal et al., 2000, 2008, 2010). Those ﬁndings were replicated in a
large retrospective cohort study in Vietnam. Interviews were con-
ducted with 10,503 women who received QS between 1989 and
1996, and a similar numberof controlswhohad IUD insertions.With
an average 16 years of post-treatment follow-up time, survival ana-
lysis found no signiﬁcant excess of reproductive tract cancer risk in
the QS group compared to the IUD recipients (Tave et al., 2012).4. Discussion
4.1. Flaws in the design of the rat CaBio
There are a number of aspects of the rat carcinogenicity study
which led to the formation of reproductive tract tumors that
negate its relevance for the clinical use of quinacrine intrauterine
administration. These include:
 the administration of quinacrine at doses that exceeded the
MTD and produced chronic toxicity and permanent damage to
the uterus;
 the use of a methylcellulose slurry rather than the clinically
designed pellets, and the methylcellulose cervical ‘plug’ to
retain the slurry; and
 the inability to produce the sought-after ﬁbrosis in the rat
uterus.
4.1.1. Administration of quinacrine at doses that exceeded the MTD
and produced chronic toxicity and permanent damage to the uterus
Dose setting for rodent carcinogenicity studies designed for
regulatory use is based on the concept of the MTD (MaximumTolerated Dose; sometimes called Minimally Toxic Dose) (ICH,
2008; OECD, 2009, 2010). This is a dose ‘‘which is predicted to pro-
duce a minimum toxic effect over the course of the carcinogenicity
study,’’ or ‘‘is just high enough to elicit signs of minimal toxicity
without signiﬁcantly altering the animal’s normal lifespan due to
effects other than carcinogenicity. The MTD should not produce
morphologic evidence of toxicity of a severity that would interfere
with the interpretation of the study’’ (ICH, 2008). The MTD is
chosen as the high dose to avoid carcinogenic and other effects sec-
ondarily associated with toxicity (Rhomberg et al., 2007).
Doses in this study were selected based on the goal of produc-
ing a ﬁbrotic occlusion (lumen closure) of the rat uterus at the high
dose. High mortality was expected and considered justiﬁed by the
need to duplicate the effect of quinacrine in the human fallopian
tube. Additional animals were therefore included in the protocol
as potential replacements for those that died shortly after dosing
(Cancel et al., 2010).
As anticipated, in many animals quinacrine administration pro-
duced immediate lethality, and chronic toxicity in the surviving
animals, which was manifested by chronic inﬂammation, necrosis,
and compensatory cell proliferation, any of which, alone, can be
considered amode of action for tumor induction. Such chronic uter-
ine destruction is far more than ‘‘minimal toxicity.’’ A signiﬁcant
increase in reproductive tract tumors was seen only in animals dis-
playing this toxicity (Tables 4 and 5), and can be considered an arti-
fact secondarily associated with toxicity. Moreover, on an
individual animal basis, this toxicity was demonstrated to be corre-
lated with tumor development. Importantly, no signiﬁcant increase
in reproductive tract tumors was observed in rats receiving the 10/
10 mg/kg dose which, based on the results of the prechronic study,
would qualify as the appropriate MTD. It was the only dose that did
not produce chronic damage to the reproductive tract.
4.1.2. Use of a methylcellulose slurry rather than the clinically
designed pellets, and the methylcellulose cervical ‘plug’ to retain the
slurry
The quinacrine was delivered as a slurry in 1% methylcellulose/
saline followed by insertion of 3% methylcellulose plugs at the
ends of each uterine horn after each administration (Cancel et al.,
2010). This is an administration route and technique with no prior
history or supporting data. Methylcellulose is a biodurable,
biologically active substance when injected intraperitoneally
(Glomski et al., 1982; Hall and Hall, 1962; Machado et al., 1966;
Pfrimmer et al., 1978; Teoh, 1961), and is not included in the for-
mulation for humans. Methylcellulose has also been shown to be
mildly irritating to the eye and skin of rabbits (Obara et al., 1992).
However, because no untreated, or sham-treated, control
groups were included in the design, there is no way to determine
the extent to which the tumors seen at the high doses were related
to the use of methylcellulose, the use of quinacrine, and/or the pos-
sible interaction of methylcellulose with quinacrine to produce
effects (i.e., chronic inﬂammation and tumors) that would not be
induced by either substance alone.
One consequence of these design parameters (i.e., instillation
techniques and/or methylcellulose) was a 20% chronic inﬂamma-
tion rate and a 100% incidence of mixed inﬂammatory cells in
the control animals (see Table 3). Inﬂammation of any type is
rarely observed in control rat uteri in 2-year carcinogenicity
studies (http://ntp.niehs.nih.gov/results/pubs/longterm/reports/
longterm/index.html).
Another concern is that there is no indication in the published
study protocol (Cancel et al., 2010) whether the instillation tech-
niques were conducted in a sterile manner. The instillation needle
passing through the non-sterile environment of the vagina has the
potential to introduce potential pathogens into the uterus. A
resulting infection, and the inability to clear the uterine contents
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mation and possibly account for the extraordinarily high incidence
of this inﬂammation in methylcellulose control animals as well as
in the quinacrine-dosed groups.
4.1.3. Inability to produce the sought-after ﬁbrosis in the rat uterus
The high dose was selected based on the anticipation that sufﬁ-
cient concentrations of quinacrine would cause ﬁbrosis and occlu-
sion in the rat uterus, similar to the ﬁbrotic occlusion seen in the
fallopian tubes of women at the therapeutic dose (Cancel et al.,
2010). However, the structures of the uterus of the rat and the fal-
lopian tube in women differ in important ways. The fallopian tube
is a relatively simple structure, i.e., the lumen is lined with a
mucosa comprised of a single layer of a mix of ciliated and non-
ciliated cells, with a thin lamina propria covered by a myometrium
of three layers of muscle tissue. In contrast, the rat uterus is highly
complex, consisting of an epithelial surface, a complex stromal and
glandular structure, and a thick wall of smooth muscle.
The experimental design of the CaBio did not address these dif-
ferences in the anatomy of the rat uterus and the human fallopian
tube (or between the rat and human uterus), nor the evidence from
earlier studies showing that the mechanism of action of quinacrine
in the human fallopian tube cannot be replicated in the rat or other
animal models, including pigs and monkeys (Dubin et al., 1984;
Fail et al., 2000; King et al., 1983; Zaneveld and Goldsmith,
1984). This was conﬁrmed in the rat CaBio. Contrary to what was
expected based on the ﬁbrotic response in women, the incidence
of ﬁbrosis in the rat reproductive tract either decreased with
respect to dose or remained equivalent to controls in quinacrine-
treated groups, even at the doses that produced chronic inﬂamma-
tion and necrosis (see Table 3). No lumen closures or occlusions of
the uterus were noted in the treated rats.
Although the rat uterus is not an appropriate surrogate for the
human fallopian tube, it is a valid organ in which to study the
potential carcinogenic activity of quinacrine, because that is the
organ that receives the majority of the exposure to quinacrine for
permanent contraception in women.
4.2. The proposed mode of action of quinacrine’s carcinogenicity in the
rat CaBio
All the evidence leads to the conclusion that chronic inﬂamma-
tion caused by high-dose quinacrine-plus-methylcellulose admin-
istration is likely responsible for the reproductive tract cancers.
While acute inﬂammation is required for recovery from injury or
infection, chronic inﬂammation often leads to disease, including
cancer. In this respect, the association between inﬂammation and
cancer is estimated to be responsible for approximately 25% of
all cancers in humans (Balkwill et al., 2005; Kundu and Surh,
2005). Animal and human studies have revealed that a number
of agents that produce chronic inﬂammation lead to tumor forma-
tion, including particulates such as asbestos and silica, and infec-
tious agents such as hepatitis B and C, Helicobacter pylori and
Schistosoma (Aggarwal et al., 2006). Medical conditions associated
with chronic inﬂammation and cellular changes, such as inﬂamma-
tory bowel disease, pancreatitis, hepatitis and prostatitis, are also
associated with an increased cancer risk (Arnott et al., 2002;
Houghton et al., 2007). Chronic inﬂammatory products can be
involved in multiple stages of tumorigenesis, including DNA dam-
age, angiogenesis and cell transformation, proliferation and inva-
sion (Mantovani, 2005).
Several byproducts of chronic inﬂammation, including reactive
oxygen (ROS) and reactive nitrogen (RNS) species, produce oxida-
tive stress that cause DNA strand breaks, cross-linking and genomic
instability (Matés et al., 2008). Proinﬂammatory products, including
cytokines, chemokines, cyclooxygenase-2, and prostaglandins,facilitate proliferation of initiated cells, suppression of apoptosis,
tumor neovascularization, histone modiﬁcation, and DNAmethyla-
tion. For a detailed analysis of the relationship between chronic
inﬂammation and cancer the reader is referred to several excellent
reviews (Aggarwal et al., 2006; Balkwill et al., 2005; Coussens and
Werb, 2002; O’Byrne and Dalgleish, 2001).
4.3. The mutagenicity of quinacrine and its relevance as a possible
mode of action for tumor induction in the rat CaBio
In vitro, quinacrine is mutagenic in Salmonella with and without
S9, producing frameshift mutations with and without S9 (Clarke
et al., 2001; Zeiger et al., 1988); mutagenic in cultured mammalian
(L5178Y) cells without S9 and negative with S9 (Clarke et al., 2001);
and clastogenic in cultured mammalian and human cells with and
without S9 (Clarke et al., 2001; Krishnaja and Chauhan, 2000;
Schuler et al., 2010). It did not induce micronuclei (MN) in rodent
bone marrow (Clarke et al., 2001) or chromosome aberrations in
cynomolgus monkey lymphocytes (Blake et al., 1983). Although
there had been earlier reports of MN induced in rodent bone mar-
row cells (Hart and Hartley-Asp, 1983; Jenssen et al., 1974), these
effects were contradicted by subsequent studies that demonstrated
that the cellular inclusions scored asMN in those studies were actu-
ally quinacrine, or other, inclusions, and notMN (Ashby et al., 1990;
Hitotsumachi et al., 1990; Maier and Schmid, 1975). Quinacrine’s
genetic activity in vitro has been attributed to its ability to interca-
late into the DNA helix without forming an adduct (Ferguson and
Denny, 2007). This weak mutagenicity was the basis for its subse-
quent testing for carcinogenicity in mice and rats.
It is well established that the mutagenicity or clastogenicity of a
substance in vitro is not equivalent to its being a carcinogen, and a
number of studies have shown that the ‘false positive’ rate for the
Ames Salmonella test is approximately 20–30% (Kirkland et al.,
2005; Zeiger, 1998) depending on the study and the mix of chemi-
cals evaluated. The (false positive) predictivity of positive respons-
es in the in vitro mammalian cell chromosome aberration test and
gene mutation tests can be higher, from 20% to 52%, depending on
the test and endpoint (Kirkland et al., 2005; Zeiger, 1998).
Because cancer can be caused through a number of mechan-
isms, the induction of cancer by a mutagenic chemical is not sufﬁ-
cient to ascribe that induction to mutagenicity. The weight of
evidence for quinacrine strongly suggests that the tumors induced
in the rat uterus at the high doses were not via a mutagenic mode
of action. This evidence includes the negative ﬁndings in the mouse
bone marrow micronucleus assay at i.p. doses up to 110 mg/kg/d
(80% of the LD50) for 3 days, negative chromosome aberration ﬁnd-
ings in lymphocytes of female monkeys dosed with quinacrine
either intra-uterine or i.v., and the fact that tumor occurrence in
the rat CaBio was strongly correlated with chronic inﬂammation
and tissue necrosis, lesions which were, in part, attributable to
the use of methylcellulose. In addition, the lack of tumorigenicity
in the mouse neonatal study when quinacrine was administered
in doses sufﬁcient to cause 20% mortality at the high dose, provides
additional support to the conclusion that the tumors seen in the rat
were not induced via a mutagenic mechanism. Validation studies
of the neonatal mouse assay have shown that substances negative
in this assay are not likely to be trans-species carcinogens or car-
cinogenic via a genotoxic mode of action (Flammang et al., 1997;
McClain et al., 2001).
4.4. The human clinical experience following quinacrine
administration (QS procedure)
The response to quinacrine in humans following intrauterine
administration has many similarities to non-malignant pleural
ﬁbrosis, which is characterized by complex interactions between
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and activation of ﬁbrinolytic pathways (Growe et al., 2013).
Speciﬁcally, quinacrine is thought to disrupt cell adhesion in the
cells of the uterotubal junction and transmural segment of the fal-
lopian tube, initiating a pro-ﬁbrotic cytokine cascade and resulting
in formation of mature collagen in the lumen of the fallopian tube
and permanent occlusion. The inﬂammation that occurs in a wom-
an’s uterus is transient and the uterus rapidly returns to normal.
The lesions reported in the CaBio rats two years after treatment at
dosesP70/70 mg/kg included abdominal cavity adhesions, atrophy,
cystic degeneration, chronic inﬂammation, necrosis, and toxicity-in-
duced uterine perforations (Cancel et al., 2010; McConnell et al.,
2010; Fail et al., 2000; this study). The cellular destruction and subse-
quent chronic inﬂammation in the rat uterine endometrium were
likely the result of the inability of theuterus toundergonormal repair
processes as a result of the initial excessive tissue damage, and are
the probable cause of the tumors reported by Cancel et al. (2010).
No evidence of unresolved wounding in the human uterus simi-
lar to that produced in the rat has been reported in the more than
35 years of follow-up of women who have received one, two, or
three administrations of QS. Histopathological examinations of
uteri following QS administration in study volunteers undergoing
hysterectomies (Bhatt et al., 1980; el-Kady et al., 1991; Laufe
et al., 1996; Merchant et al., 1995; Zipper et al., 1970) showed that
the endometrium rapidly returned to normal after instillation of
quinacrine. This was further conﬁrmed with post-QS sonographic
studies (Ferreira et al., 2003), post-administration biopsies (Lu
et al., 2003), and also by uterine hysteroscopy following QS (El
Sahwi et al., 1992, 2003).
These studies showed that tissue damage to the human
endometrium occurs immediately after quinacrine administration,
but that the effect is transient and the uterus rapidly returns to nor-
mal, usually within two menstrual cycles, with no chronic inﬂam-
mation or persistent necrosis being seen in the fallopian tubes or
uterus. Permanent changes were limited to specialized cells of the
fallopian tube, and lumen closure resulting from the development
of collagenous scar tissue was limited to approximately 2–3 mm
of the intramural portion of the tube (Ferreira et al., 2003; Zipper
et al., 1970). None of the lesions seen in the rat CaBio were observed
in any of these studies, and none of the collagenous scar tissue seen
in women was seen in the treated rats.5. Conclusion
The weight of evidence from rodent studies, mechanistic inves-
tigations, human clinical observations, and epidemiology studies
supports the conclusion that the mode of action leading to the
tumors seen in the rat CaBio was necrosis and compensatory cell
proliferation in the presence of chronic inﬂammation of the repro-
ductive tract, brought about by the high, toxic doses of quinacrine-
plus-methylcellulose. Tumors were not produced in the absence of
these chronic toxicities. Based on the different mode of quinacrine
administration (pellets instead of methylcellulose slurry) and the
absence of chronic toxicity and tumors in women receiving QS, it
can be concluded that the mode of action of tumor induction in
the rat is not relevant to its use in women undergoing permanent
contraception with quinacrine. This conclusion is supported by the
human epidemiology studies that have demonstrated no increase
in reproductive tract tumors in women who have received QS
treatment compared to women using other forms of contraception.Funding source
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